Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L
Department of Clinical Pathomorphology, Academy of Medicine, Poznan, Poland.
Int J Cancer. 1994 Oct 1;59(1):11-6. doi: 10.1002/ijc.2910590104.
Two different oncofetal fibronectins (FN) have been reported: one, generated by O-glycosylation in the splicing region IIICS that is recognized by monoclonal antibody (MAb) FDC-6, and another, recognized by MAb BC-I, generated by the alternative splicing of the FN pre-mRNA which includes an extra type-III repeat called ED-B. Using these and 2 other MAbs (IST-4 which recognizes all different FN isoforms and IST-6 which recognizes only the FN molecules that do not include the ED-B sequence) we have immunohistochemically studied 171 normal, hyperplastic and neoplastic breast-tissue specimens. Although all normal specimens reacted strongly with MAbs IST-4 and IST-6, they did not show the presence of oncofetal FNs as established by the use of BC-I and FDC-6. In contrast, out of the 97 cases of invasive ductal carcinomas studied, 90 (93%) and 96 (99%) reacted positively with BC-I and FDC-6, respectively, the reaction being observed in the tumoral stroma connective tissue and in tumoral vessels. Furthermore, invasive lobular carcinoma showed less intense and less frequent staining with BC-1 and FDC-6 (10 and 11 out of 14, respectively). We found differences in the distribution of the 2 oncofetal fibronectin isoforms within the same specimens. The most remarkable difference was observed in the tumoral vessels: in invasive ductal carcinoma MAb BC-1 revealed a positive reaction with vessels in 78% of cases while FDC-6 showed such a reaction in only 59% of cases.
已有报道称存在两种不同的癌胚纤连蛋白(FN):一种是在剪接区域IIICS通过O-糖基化产生的,可被单克隆抗体(MAb)FDC-6识别;另一种是由FN前体mRNA的可变剪接产生的,可被MAb BC-1识别,该可变剪接包含一个额外的III型重复序列,称为ED-B。使用这些以及另外两种单克隆抗体(识别所有不同FN异构体的IST-4和仅识别不包含ED-B序列的FN分子的IST-6),我们对171例正常、增生性和肿瘤性乳腺组织标本进行了免疫组织化学研究。尽管所有正常标本与单克隆抗体IST-4和IST-6反应强烈,但使用BC-1和FDC-6检测时,它们并未显示癌胚FN的存在。相比之下,在研究的97例浸润性导管癌病例中,分别有90例(93%)和96例(99%)与BC-1和FDC-6呈阳性反应,在肿瘤间质结缔组织和肿瘤血管中均观察到该反应。此外,浸润性小叶癌与BC-1和FDC-6的染色强度较低且频率较低(分别为14例中的10例和11例)。我们发现在同一标本中两种癌胚纤连蛋白异构体的分布存在差异。最显著的差异出现在肿瘤血管中:在浸润性导管癌中,MAb BC-1在78%的病例中显示血管呈阳性反应,而FDC-6仅在59%的病例中显示该反应。